M John Chapman
Overview
Explore the profile of M John Chapman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
18636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Krauss R, Remaley A, Chapman M
J Clin Lipidol
. 2022 Mar;
16(3):250-252.
PMID: 35292206
No abstract available.
12.
Chapman M
Curr Opin Endocrinol Diabetes Obes
. 2022 Jan;
29(2):112-123.
PMID: 34980868
Purpose Of Review: To critically appraise new insights into HDL structure and function in type 1 diabetes (T1DM) and type 2 diabetes (T2DM). Recent Findings: In young T1DM patients with...
13.
Durlach V, Bonnefont-Rousselot D, Boccara F, Varret M, Di-Filippo Charcosset M, Cariou B, et al.
Arch Cardiovasc Dis
. 2021 Nov;
114(12):828-847.
PMID: 34840125
Lipoprotein(a) is an apolipoprotein B100-containing low-density lipoprotein-like particle that is rich in cholesterol, and is associated with a second major protein, apolipoprotein(a). Apolipoprotein(a) possesses structural similarity to plasminogen but lacks...
14.
Ginsberg H, Packard C, Chapman M, Boren J, Aguilar-Salinas C, Averna M, et al.
Eur Heart J
. 2021 Sep;
42(47):4791-4806.
PMID: 34472586
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL),...
15.
Packard C, Chapman M, Sibartie M, Laufs U, Masana L
Heart
. 2021 Apr;
107(17):1369-1375.
PMID: 33795379
Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia from the European Society of Cardiology...
16.
Bhatt D, Hull M, Song M, Van Hulle C, Carlsson C, Chapman M, et al.
Eur Heart J Suppl
. 2020 Oct;
22(Suppl J):J54-J64.
PMID: 33061868
The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties...
17.
Parhofer K, Chapman M, Nordestgaard B
Eur Heart J Suppl
. 2020 Oct;
22(Suppl J):J21-J33.
PMID: 33061865
Although low-density lipoprotein cholesterol lowering is effective in atherosclerotic cardiovascular disease (ASCVD) prevention, considerable 'lipid-associated' residual risk remains, particularly in patients with mild-to-moderate hypertriglyceridaemia (2-10 mmol/L; 176-880 mg/dL). Triglyceride (TG)-rich...
18.
Chapman M, Giral P, Therond P
Clin Chem
. 2020 Sep;
66(9):1136-1139.
PMID: 32870985
No abstract available.
19.
Katzmann J, Packard C, Chapman M, Katzmann I, Laufs U
J Am Coll Cardiol
. 2020 Aug;
76(5):563-579.
PMID: 32731935
There is an unmet clinical need to reduce residual cardiovascular risk attributable to apolipoprotein B-containing lipoproteins, particularly low-density lipoprotein and remnant particles. Pharmacological targeting of messenger RNA represents an emerging,...
20.
Gallo A, Charriere S, Vimont A, Chapman M, Angoulvant D, Boccara F, et al.
Atherosclerosis
. 2020 Jul;
306:41-49.
PMID: 32688103
Background And Aims: Patients with heterozygous familial hypercholesterolemia (HeFH) present elevated cardiovascular (CV) risk. Current CV risk stratification algorithms developed for the general population are not adapted for heFH patients....